{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:06:20Z","timestamp":1760241980578,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>As a follow-up to our previous studies on differently substituted 1,4-dihydropyridines endowed with a peculiar cardiac selectivity, in this paper, a small series of hybrid compounds bearing the pharmacophore fragment of lidoflazine in position 2 or 3 on a 4-(xanthen-9-one)-dihydropyridine core was reported. Lidoflazine was selected due to our promising previously reported data, and the xanthen-9-one substituent was introduced in position 4 of the dihydropyridine scaffold based on the cardiac selectivity observed in several of our studies. The new hybrid compounds were tested to assess cardiac and vascular activities, and the data were evaluated in comparison with those previously obtained for 4-(xanthen-9-one)-dihydropyridines and lidoflazine\u2013nifedipine hybrid compounds. The functional studies indicated an interesting peculiar selectivity for the cardiac parameter inotropy, in particular when the lidoflazine fragment was introduced in position 2 of the dihydropyridine scaffold (4a\u2013e), and thus a possible preferential binding with the Cav 1.2 isoform of l-type calcium channels, which are mainly involved in cardiac contractility.<\/jats:p>","DOI":"10.3390\/molecules23123088","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T03:31:33Z","timestamp":1543289493000},"page":"3088","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular Profile of Xanthone-Based 1,4 Dihydropyridines Bearing a Lidoflazine Pharmacophore Fragment"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-4743","authenticated-orcid":false,"given":"Alessandra","family":"Bisi","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Micucci","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-5377","authenticated-orcid":false,"given":"Silvia","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-5579","authenticated-orcid":false,"given":"Federica","family":"Belluti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-9740","authenticated-orcid":false,"given":"Roberta","family":"Budriesi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8028-8758","authenticated-orcid":false,"given":"Angela","family":"Rampa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"ref_1","unstructured":"(2018, May 24). The Top 10 Causes of Death. Available online: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_2","first-page":"e29","article-title":"Heart disease and stroke statistics\u20142015 update: A report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.106.647933","article-title":"Sudden cardiac death: Better understanding of risks, mechanisms and treatment","volume":"114","author":"Lopshire","year":"2006","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Guidelines Committee (2013). 2013 European society of hypertension-European society of cardiology Guidelines for the management of arterial hypertension. Eur. Heart J., 34, 2159\u20132219.","DOI":"10.1093\/eurheartj\/eht151"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1874467208666150507105845","article-title":"Pharmacology of l-type calcium channels: Novel drugs for old targets?","volume":"8","author":"Striessnig","year":"2015","journal-title":"Curr. Mol. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.tips.2011.02.012","article-title":"Structural and functional differences between l-type calcium channels: Crucial issues for future selective targeting","volume":"6","author":"Zuccotti","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_7","first-page":"111","article-title":"Cardiovascular agents and endocrines","volume":"Volume 3","author":"Abraham","year":"2003","journal-title":"Burger\u2019s Medicinal Chemistry and Drug Discovery"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.2174\/092986711797535173","article-title":"1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (Part 1): Action in ion channels and GPCRs","volume":"18","author":"Ioan","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/cmdc.201600067","article-title":"Polypharmacology in drug development: A minireview of current technologies","volume":"11","author":"Tan","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejmech.2016.08.039","article-title":"Hybrid molecules: The privileged scaffolds for various pharmaceuticals","volume":"124","author":"Shaveta","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/0968-0896(96)00155-1","article-title":"1,4-Dihydropyridines bearing a pharmacophoric fragment of lidoflazine","volume":"10","author":"Chiarini","year":"1996","journal-title":"Bioorg. Med. Chem."},{"key":"ref_12","first-page":"122","article-title":"Xanthone 1,4-dihydropyridine derivatives with a potent selective bradycardic effect","volume":"40","author":"Valenti","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"ref_13","first-page":"797","article-title":"Negative inotropic and chronotropic activity of calcium channel ligands possessing a xanthone 1,4-dihydropyridine backbone","volume":"42","author":"Chiarini","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"ref_14","first-page":"705","article-title":"4-heterotricyclic substituted 1,4-dihydropyridines with a potent selective bradycardic effect","volume":"41","author":"Rampa","year":"1991","journal-title":"Arzneimittelforschung"},{"key":"ref_15","first-page":"1491","article-title":"SAR studies in the field of Ca-antagonists: 2-substituted 1,4-dihydropyridines with a xanthone backbone","volume":"11","author":"Bisi","year":"1993","journal-title":"Farmaco"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2017.00286","article-title":"Discovery and Development of Calcium Channel Blockers","volume":"8","author":"Godfraind","year":"2017","journal-title":"Front. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1081\/NCN-59711","article-title":"Lidoflazine combined with nucleotide precursors increase ATP content and adenosine production in cardiomyocytes","volume":"24","author":"Kalsi","year":"2005","journal-title":"Nucleoside Nucleotide Nucleic Acid"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/jm00319a016","article-title":"\u03b2-(N-Piperazino)dimethylacetanilides and their local anesthetic activity","volume":"9","author":"Foye","year":"1966","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3891\/acta.chem.scand.15-1367","article-title":"Piperazine compounds containing a 2,6-dimethylphenyl residue","volume":"15","author":"Dahlbom","year":"1961","journal-title":"Acta Chem. Scand."},{"key":"ref_20","unstructured":"Tallarida, R.J., and Murray, R.B. (1987). Manual of Pharmacological Calculations with Computer Programs, Springer."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.2174\/092986712802884204","article-title":"1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (Part 2): Action in other targets and antitargets","volume":"19","author":"Carosati","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1248\/cpb.27.1426","article-title":"Synthesis of new water soluble dihydropyridine vasodilators","volume":"27","author":"Iwanami","year":"1979","journal-title":"Chem. Pharm. Bull."},{"key":"ref_23","first-page":"407","article-title":"Synthesis and comparative pharmacological studies of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylates with non-identical ester functions","volume":"31","author":"Meyer","year":"1981","journal-title":"Arzneimittforschung"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1089\/jmf.2015.0072","article-title":"Hibiscus Sabdariffa L. flowers and Olea Europea L. leaves extract-based formulation for hypertension care: In vitro efficacy and toxicological profile","volume":"19","author":"Micucci","year":"2016","journal-title":"J. Med. Food"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Motulsky, H., and Christopoulos, A. (2003). Fitting Models to Biological Data Using Linear and Non Linear Regression, GraphPad Software Inc.. Available online: www.graphpad.com.","DOI":"10.1093\/oso\/9780195171792.001.0001"},{"key":"ref_26","unstructured":"Motulsky, H.J. (2007). Prism 5 Statistics Guide, GraphPad Software Inc.. Available online: www.graphpad.com."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/12\/3088\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:32:17Z","timestamp":1760196737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/12\/3088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["molecules23123088"],"URL":"https:\/\/doi.org\/10.3390\/molecules23123088","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2018,11,27]]}}}